SS-31 Community Reports
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
How can it help me?
Wiki article — community perspective
Companion raw digest:
Evidence tier: throughout
Last updated: 2026-07-10
Cross-refs: *peptides/mots-c* · *peptides/nad-plus* · *peptides/epithalon*
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
What should I avoid combining — and what's synergistic?
SS-31 Community Reports doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
We don't have a verified affiliate source for SS-31 Community Reports yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
Wiki article — community perspective
Companion raw digest:
Evidence tier: throughout
Last updated: 2026-07-10
Cross-refs: *peptides/mots-c* · *peptides/nad-plus* · *peptides/epithalon*
Who reports the strongest results
People with fatigue that hasn’t responded to lifestyle optimization — adequate sleep, good nutrition, exercise, stress management — and is likely driven by underlying mitochondrial dysfunction or aging-related mitochondrial decline. SS-31 works at the organelle level where lifestyle changes don’t reach.
Also strong results in cardiac endurance contexts and, per the Tony Pemberton account, kidney biological age markers.
What the community actually says
The energy experience — specific and credible
The most consistent community framing is “the floor went up” — not stimulant energy, not forced performance, but a genuine lifting of baseline energy capacity. Described as what people with good mitochondrial function experience as normal, now accessible.
Specific elements:
- Less fatigue accumulation during physical activity
- Cardiorespiratory endurance improved — longer sessions at the same perceived effort
- Recovery between high-intensity efforts faster
- Onset: typically 2–4 weeks before noticeable change
The FDA validation
In September 2025, elamipretide received FDA approval for Barth syndrome — a rare mitochondrial disease. The clinical dose is 40 mg; community uses 5–10 mg. Community reaction: “if WADA bans MOTS-c and FDA approves SS-31 for a mitochondrial disease, the mitochondrial mechanisms are real.” The approval is meaningful validation.
The Tony Pemberton kidney finding
Tony Pemberton documented organ-specific biological age markers improving after SS-31 cycles, with kidney function being the notable finding. This circulates in longevity communities as a reference for organ protection effects beyond energy and cardiac application.
Protocol as used by the community
Dose: 5–10 mg SubQ per injection; 5 mg starting; escalate to 10 mg if insufficient response
Frequency: Daily or every other day; some users 3× per week
Mito stack with MOTS-c: SS-31 (hardware) + MOTS-c (software). See *peptides/mots-c*. Additive effects documented in community.
Cycling: 8 weeks on / 4 off; some run continuous with quarterly breaks. No tolerance documented.
Side effects
Very mild; among the best-tolerated peptides.
- Injection site redness and occasional mild pain (more than some other SubQ peptides)
- Headache — rare; initial days
- No significant systemic side effects at community doses (5–10 mg vs 40 mg FDA dose)
Why people don't respond — community's analysis
- Underdosing — most common; 5 mg may be below effective threshold for some; 10 mg is becoming the community’s minimum recommendation
- Mitochondrial dysfunction not the primary issue — SS-31 targets mitochondria specifically; hormonal, thyroid, or nutritional fatigue won’t respond
- Short trial — needs 3–4 weeks minimum
- Product quality — relevant but less documented than for some peptides
Cross-references
*peptides/mots-c*— the complementary mito stack partner*peptides/nad-plus*— another mitochondrial energy pathway approach*peptides/epithalon*— often combined in longevity stacks
Commercial note
SS-31 is available through Alyve — use code OHM-15 at checkout for 15% off.